An Act to direct the Board of Medicine to amend its regulations regarding office-based buprenorphine treatment to require providers to offer counseling or referral to counseling.
Summary
HB712 directs the Virginia Board of Medicine to amend its regulations for office-based buprenorphine treatment so that providers must offer counseling or a referral to counseling to patients receiving treatment for opioid use disorder, when clinically necessary and mutually agreed upon. The bill also makes clear that a patient’s refusal of counseling does not bar access to office-based buprenorphine treatment.
In practical terms, the measure preserves access to medication-assisted treatment while adding a counseling-offer requirement to the regulatory framework. It does not create a new criminal penalty or mandate counseling in every case; instead, it ties the counseling offer to clinical appropriateness and patient agreement, while protecting continued treatment if counseling is declined.
Impact
The bill requires the Board of Medicine to revise its regulations governing office-based buprenorphine treatment, affecting providers who prescribe buprenorphine for opioid use disorder and the patients they serve. It reinforces the role of counseling in treatment planning but prevents counseling refusal from being used to deny medication-based treatment, thereby shaping how office-based opioid treatment programs operate in Virginia without directly changing the underlying statute on buprenorphine prescribing.
Sentiment
The bill appears to have enjoyed broad bipartisan support and little visible opposition. It advanced unanimously or near-unanimously through subcommittee, committee, and floor votes in both chambers, and it was ultimately enacted as Chapter 207. The vote history suggests general agreement that counseling should be encouraged alongside buprenorphine treatment while maintaining access to care.
Contention
There is little evidence of major contention in the available record. The main policy balance is between encouraging counseling as part of opioid use disorder treatment and ensuring that patients are not denied buprenorphine if they decline counseling. Any concern would likely come from those wary of additional treatment requirements versus those who favor stronger counseling integration, but the bill’s language resolves that tension by making counseling an offer or referral rather than a condition of treatment.